Select Publications
Journal articles
2017, 'Canagliflozin slows progression of renal function decline independently of glycemic effects', Journal of the American Society of Nephrology, 28, pp. 368 - 375, http://dx.doi.org/10.1681/ASN.2016030278
,2017, 'Chronic kidney disease and the global NCDs agenda', BMJ Global Health, 2, http://dx.doi.org/10.1136/bmjgh-2017-000380
,2017, 'Comparative Effectiveness of 12 Treatment Strategies for Preventing Contrast-Induced Acute Kidney Injury: A Systematic Review and Bayesian Network Meta-analysis', American Journal of Kidney Diseases, 69, pp. 69 - 77, http://dx.doi.org/10.1053/j.ajkd.2016.07.033
,2017, 'Side effects and tolerability of combination blood pressure lowering according to blood pressure levels: An analysis of the PROGRESS and ADVANCEtrials', Journal of Hypertension, 35, pp. 1318 - 1325, http://dx.doi.org/10.1097/HJH.0000000000001287
,2016, 'Commentary', Annals of Internal Medicine, 165, pp. JC71, http://dx.doi.org/10.7326/ACPJC-2016-165-12-071
,2016, 'Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference', Kidney International, 90, pp. 1175 - 1183, http://dx.doi.org/10.1016/j.kint.2016.09.010
,2016, 'A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension', The Lancet, 388, pp. 2665 - 2712, http://dx.doi.org/10.1016/S0140-6736(16)31134-5
,2016, 'Knowing what we do not know: statin therapy in advanced chronic kidney disease', The Lancet Diabetes and Endocrinology, 4, pp. 801 - 803, http://dx.doi.org/10.1016/S2213-8587(16)30192-9
,2016, 'The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis', American Journal of Kidney Diseases, 68, pp. 591 - 598, http://dx.doi.org/10.1053/j.ajkd.2016.04.011
,2016, 'The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis', American Journal of Kidney Diseases, 68, pp. 554 - 563, http://dx.doi.org/10.1053/j.ajkd.2016.03.418
,2016, 'Sharing data from cardiovascular clinical trials \- a proposal', New England Journal of Medicine, 375, pp. 407 - 409, http://dx.doi.org/10.1056/NEJMp1605260
,2016, 'Effects of the mediterranean diet on cardiovascular outcomes-a systematic review and meta-analysis', PLoS ONE, 11, http://dx.doi.org/10.1371/journal.pone.0159252
,2016, 'Guideline for the diagnosis and management of hypertension in adults — 2016', Medical Journal of Australia, 205, pp. 85 - 89, http://dx.doi.org/10.5694/mja16.00526
,2016, 'Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF', Journal of the American College of Cardiology, 67, pp. 2888 - 2899, http://dx.doi.org/10.1016/j.jacc.2016.02.082
,2016, 'A randomized trial of intensive versus standard blood-pressure control [10]', New England Journal of Medicine, 374, pp. 2295, http://dx.doi.org/10.1056/NEJMc1602668
,2016, 'The β-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) feasibility study: A randomized controlled trial', American Journal of Kidney Diseases, 67, pp. 902 - 911, http://dx.doi.org/10.1053/j.ajkd.2015.10.029
,2016, 'Interventions for lowering plasma homocysteine levels in dialysis patients', Cochrane Database of Systematic Reviews, 2016, http://dx.doi.org/10.1002/14651858.CD004683.pub4
,2016, 'Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: A systematic review and meta-analysis', The Lancet Diabetes and Endocrinology, 4, pp. 411 - 419, http://dx.doi.org/10.1016/S2213-8587(16)00052-8
,2016, 'Long-term benefits of intensive glucose Control for preventing end-stage kidney disease: ADVANCE-ON', Diabetes Care, 39, pp. 694 - 700, http://dx.doi.org/10.2337/dc15-2322
,2016, 'Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers', European Journal of Preventive Cardiology, 23, pp. 758 - 768, http://dx.doi.org/10.1177/2047487315598709
,2016, 'Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients with CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials', American Journal of Kidney Diseases, 67, pp. 728 - 741, http://dx.doi.org/10.1053/j.ajkd.2015.10.011
,2016, 'Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end-stage kidney disease', Cochrane Database of Systematic Reviews, 2016, http://dx.doi.org/10.1002/14651858.CD009631.pub2
,2016, 'ALTITUDE: Defining a ceiling for blockade of the renin-angiotensin system?', The Lancet Diabetes and Endocrinology, 4, pp. 289 - 290, http://dx.doi.org/10.1016/S2213-8587(15)00518-5
,2016, 'The Affordable Dialysis Prize steams ahead', The Lancet, 387, pp. 1040, http://dx.doi.org/10.1016/S0140-6736(16)00657-7
,2016, 'International trials in middle-income countries: different local scenarios require different ethical approaches', Journal of the Royal Society of Medicine, 109, pp. 47 - 51, http://dx.doi.org/10.1177/0141076815608854
,2016, 'Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: Updated systematic review and meta-analysis', The Lancet, 387, pp. 435 - 443, http://dx.doi.org/10.1016/S0140-6736(15)00805-3
,2016, 'The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial', Redox Report, 21, pp. 14 - 23, http://dx.doi.org/10.1179/1351000215Y.0000000022
,2016, 'Effects of ischaemic conditioning on major clinical outcomes in people undergoing invasive procedures: Systematic review and meta-analysis', BMJ (Online), 355, http://dx.doi.org/10.1136/bmj.i5599
,2016, 'Efficacy and safety of canagliflozin when used in conjunction with incretin-mimetic therapy in patients with type 2 diabetes', Diabetes, Obesity and Metabolism, 18, pp. 82 - 91, http://dx.doi.org/10.1111/dom.12589
,2016, 'MP221EFFECTS OF ISCHAEMIC CONDITIONING ON MAJOR CLINICAL OUTCOMES IN PEOPLE UNDERGOING INVASIVE PROCEDURES: A SYSTEMATIC REVIEW AND METAANALYSIS', Nephrology Dialysis Transplantation, 31, pp. i413 - i413, http://dx.doi.org/10.1093/ndt/gfw187.27
,2016, 'National Heart Foundation Hypertension Guideline - 2016', Heart, Lung and Circulation, 25, pp. S18 - S18, http://dx.doi.org/10.1016/j.hlc.2016.06.039
,2015, 'Redefining blood-pressure targets - SPRINT starts the marathon', New England Journal of Medicine, 373, pp. 2175 - 2178, http://dx.doi.org/10.1056/NEJMe1513301
,2015, 'Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA-T2D™ trial', Diabetes and Vascular Disease Research, 12, pp. 455 - 462, http://dx.doi.org/10.1177/1479164115579002
,2015, 'HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis', Sao Paulo Medical Journal, 133, pp. 541, http://dx.doi.org/10.1590/1516-3180.20151336T2
,2015, 'Renal effects of canagliflozin in type 2 diabetes mellitus', Current Medical Research and Opinion, 31, pp. 2219 - 2231, http://dx.doi.org/10.1185/03007995.2015.1092128
,2015, 'Relationship between levels of advanced glycation end products and their soluble receptor and adverse outcomes in adults with type 2 diabetes', Diabetes Care, 38, pp. 1891 - 1897, http://dx.doi.org/10.2337/dc15-0925
,2015, 'Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial', Diabetes Therapy, 6, pp. 289 - 302, http://dx.doi.org/10.1007/s13300-015-0117-z
,2015, 'Relationship between serum uric acid levels and chronic kidney disease in a Japanese cohort with normal or mildly reduced kidney function', PLoS ONE, 10, http://dx.doi.org/10.1371/journal.pone.0137449
,2015, 'Predictors of atrasentan-associated fluid retention and change in albuminuria in patients with diabetic nephropathy', Clinical Journal of the American Society of Nephrology, 10, pp. 1568 - 1574, http://dx.doi.org/10.2215/CJN.00570115
,2015, 'Assessing the validity of surrogate outcomes for ESRD: A meta-analysis', Journal of the American Society of Nephrology, 26, pp. 2289 - 2302, http://dx.doi.org/10.1681/ASN.2014040396
,2015, 'First Light after the Long Night: A Follow-up Report of the Randomized FHN Nocturnal Trial', American Journal of Kidney Diseases, 66, pp. 379 - 382, http://dx.doi.org/10.1053/j.ajkd.2015.06.007
,2015, 'Kidney Disease End Points in a Pooled Analysis of Individual Patient-Level Data from a Large Clinical Trials Program of the Dipeptidyl Peptidase 4 Inhibitor Linagliptin in Type 2 Diabetes', American Journal of Kidney Diseases, 66, pp. 441 - 449, http://dx.doi.org/10.1053/j.ajkd.2015.03.024
,2015, 'Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: A secondary analysis of the HERO trial', Canadian Journal of Kidney Health and Disease, 2, http://dx.doi.org/10.1186/s40697-015-0066-5
,2015, 'Research Priorities in CKD: Report of a National Workshop Conducted in Australia', American Journal of Kidney Diseases, 66, pp. 212 - 222, http://dx.doi.org/10.1053/j.ajkd.2015.02.341
,2015, 'Erratum. The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients With type 2 diabetes. Diabetes Care 2014;37:295-303', Diabetes Care, 38, pp. 1393, http://dx.doi.org/10.2337/dc15-er07
,2015, 'Worldwide access to treatment for end-stage kidney disease: A systematic review', The Lancet, 385, pp. 1975 - 1982, http://dx.doi.org/10.1016/S0140-6736(14)61601-9
,2015, 'Interventions for lowering plasma homocysteine levels in kidney transplant recipients', Cochrane Database of Systematic Reviews, 2015, http://dx.doi.org/10.1002/14651858.CD007910.pub2
,2015, 'Clinical characteristics of IgA nephropathy associated with low complement 4 levels', Renal Failure, 37, pp. 424 - 432, http://dx.doi.org/10.3109/0886022X.2014.994408
,2015, 'Design and participant baseline characteristics of 'A Clinical Trial of IntensiVE Dialysis': The ACTIVE Dialysis Study', Nephrology, 20, pp. 257 - 265, http://dx.doi.org/10.1111/nep.12385
,2015, 'Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: A meta-analysis of randomised trials', The Lancet, 385, pp. 867 - 874, http://dx.doi.org/10.1016/S0140-6736(14)61171-5
,